RT Journal Article SR Electronic T1 The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab JF Annals of the Rheumatic Diseases JO Ann Rheum Dis FD BMJ Publishing Group Ltd and European League Against Rheumatism SP 1888 OP 1890 DO 10.1136/annrheumdis-2013-203353 VO 72 IS 11 A1 Ch Plasencia A1 D Pascual-Salcedo A1 P Alcocer A1 M G Bonilla A1 A Villalba A1 D Peiteado A1 F Arribas A1 J Díez A1 M T Lopez-Casla A1 E Martín-Mola A1 A Balsa YR 2013 UL http://ard.bmj.com/content/72/11/1888.1.abstract AB